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Renal function in patients with non-dialysis
chronic kidney disease receiving
intravenous ferric carboxymaltose: an
analysis of the randomized FIND-CKD trial
Iain C. Macdougall1*, Andreas H. Bock2, Fernando Carrera3, Kai-Uwe Eckardt4, Carlo Gaillard5, David Van Wyck6,
Yvonne Meier7, Sylvain Larroque7, Simon D. Roger8 and on behalf of the FIND-CKD Study investigators
Abstract
Background: Preclinical studies demonstrate renal proximal tubular injury after administration of some intravenous
iron preparations but clinical data on renal effects of intravenous iron are sparse.
Methods: FIND-CKD was a 56-week, randomized, open-label, multicenter study in which patients with non-dialysis
dependent chronic kidney disease (ND-CKD), anemia and iron deficiency without erythropoiesis-stimulating agent
therapy received intravenous ferric carboxymaltose (FCM), targeting either higher (400–600 μg/L) or lower (100–200 μg/L)
ferritin values, or oral iron.
Results: Mean (SD) eGFR at baseline was 34.9 (11.3), 32.8 (10.8) and 34.2 (12.3) mL/min/1.73 m2 in the high ferritin FCM
(n = 97), low ferritin FCM (n = 89) and oral iron (n = 167) groups, respectively. Corresponding values at month 12 were
35.6 (13.8), 32.1 (12.7) and 33.4 (14.5) mL/min/1.73 m2. The pre-specified endpoint of mean (SE) change in eGFR from
baseline to month 12 was +0.7 (0.9) mL/min/1.73 m2 with high ferritin FCM (p = 0.15 versus oral iron), -0.9
(0.9) mL/min/1.73 m2 with low ferritin FCM (p= 0.99 versus oral iron) and -0.9 (0.7) mL/min/1.73 m2 with oral iron. No
significant association was detected between quartiles of FCM dose, change in ferritin or change in TSAT versus change
in eGFR. Dialysis initiation was similar between groups. Renal adverse events were rare, with no indication of
between-group differences.
Conclusion: Intravenous FCM at doses that maintained ferritin levels of 100–200 μg/L or 400–600 μg/L did
not negatively impact renal function (eGFR) in patients with ND-CKD over 12 months versus oral iron, and
eGFR remained stable. These findings show no evidence of renal toxicity following intravenous FCM over a
1-year period.
Trial registrations: ClinicalTrials.gov NCT00994318 (first registration 12 October 2009).
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Background
The use of iron therapy to manage renal anemia in
patients with chronic kidney disease (CKD) has
increased significantly in recent years [1], partly in re-
sponse to concerns about the safety of erythropoiesis-
stimulating agent (ESA) therapies [2, 3]. Randomized
trials have shown intravenous (IV) iron therapy to be
more effective than oral iron in terms of replenishing
depleted iron stores and improving anemia in patients
on dialysis [4–6]. In non-dialysis dependent CKD (ND-
CKD), trials have confirmed the benefits of IV versus
oral iron therapy but have typically been no longer than
8 weeks in duration [7–11]. Recently, the randomized
56-week FIND-CKD study compared IV ferric carboxy-
maltose (FCM) versus oral iron in patients with
ND-CKD, anemia, and iron deficiency not receiving ESA
therapy [12]. Intravenous FCM targeting a ferritin level
of 400–600 μg/L delayed and/or reduced the need for
other anemia management (including ESAs) significantly
at 1 year compared to patients receiving oral iron, and
the hematopoietic response was more rapid.
However, concerns exist about the potential renal
toxicity of IV iron therapy [13]. Rapid release of large
amounts of iron into the bloodstream could generate
‘free’ iron in the circulation (non-transferrin bound iron,
NTBI) which may promote oxidative stress [14, 15].
Some IV iron complexes such as ferric gluconate contain
weakly-bound iron that is released readily and quickly
[15]. In contrast, animal models have shown, that oxida-
tive stress does not increase with more stable IV iron
complexes such as FCM [16–18]. Clinical evidence relat-
ing to a possible effect of IV iron therapy on renal
function is limited. Single-dose and short-term (5-week)
studies from one center have indicated that iron sucrose
may induce renal injury mediated by oxidative stress and
inflammation [19–23]. However, the recently published
REVOKE study, which randomized patients with ND-
CKD to IV iron sucrose or oral iron, showed neither a
difference in renal function decline (based on GFR
measured by iothalamate clearance) nor in proteinuria
during follow-up lasting up to 2 years [24]. Confirmatory
data are clearly important.
The FIND-CKD trial included protocol-specified moni-
toring of renal function in over 600 patients with ND-CKD,
based on estimated GFR (eGFR), throughout the 1-year
study [25]. Data were analyzed to compare renal outcomes
in patients randomized to IV FCM using two different
dosing regimens aiming for different target ferritin concen-
trations, with those in patients receiving oral iron.
Methods
Study design
FIND-CKD was a 56-week, open-label, multicenter,
prospective, randomized, three-arm study undertaken
during December 2009 to January 2012 at 193 neph-
rology centers in 20 countries (ClinicalTrials.gov
NCT00994318) [25].
Patient population
Adult patients (≥18 years) with ND-CKD were eligible for
inclusion if (a) at least one Hb level was between 9 and
11 g/dL within 4 weeks of randomization, (b) any ferritin
level was <100 μg/L, or <200 μg/L with transferrin
saturation (TSAT) <20%, within 4 weeks of randomization,
(c) eGFR was ≤60 mL/min/1.73 m2 (four-variable Modifica-
tion of Diet in Renal Disease [MDRD-4] equation
[26]), the prior rate of eGFR loss was ≤12 mL/min/
1.73 m2/year and predicted eGFR at 12 months based
on previous decline was ≥15 mL/min/1.73 m2, and
(d) no ESA had been administered within 4 months
prior to randomization. Estimates of prior eGFR loss
were based on at least two values over at least
4 weeks prior to randomization, and preferably three
values over at least 3 months.
Key exclusion criteria included current dialysis, an-
ticipated dialysis or transplantation during the study,
anemia due to reasons other than iron deficiency, a
documented history of discontinuing oral iron prod-
ucts due to significant gastrointestinal distress, known
active infection, C-reactive protein >20 mg/L, overt
bleeding, active malignancy, chronic liver disease,
concomitant New York Heart Association Class IV
heart failure and poorly controlled hypertension
(>160 mmHg systolic pressure or >100 mmHg dia-
stolic pressure).
Randomization and intervention
Eligible patients were randomized centrally via a central
interactive voice-response system in a 1:1:2 ratio to high
ferritin FCM, low ferritin FCM or oral iron. The dose of
FCM (Ferinject®, Vifor International, St Gallen,
Switzerland) in the high ferritin and low ferritin FCM
groups was adjusted to target a ferritin level of 400
−600 μg/L and 100–200 μg/L, respectively. An initial
single dose was administered on day 0: 1000 mg iron as
FCM in the high ferritin FCM group (500 mg iron on
days 0 and 7 in patients weighing ≤66 kg) and 200 mg
iron as FCM in the low ferritin FCM group if ferritin
was <100 μg/L. During weeks 4 to 48, FCM was admin-
istered every 4 weeks in the high ferritin FCM group at
a dose of 500 mg iron if ferritin was in the range 200 to
<400 μg/L, and at a dose of 1000 mg iron if ferritin was
<200 μg/L, and in the low ferritin FCM group at a dose
of 200 mg iron if ferritin was <100 μg/L. In both groups,
dosing was withheld if TSAT was ≥40%. Oral iron ther-
apy consisted of commercially-available ferrous sulfate at
a dose of 304 mg (100 mg of iron) twice daily to week
52. During the first 8 weeks after randomization,
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patients were not to receive ESAs, blood transfusion or
any anemia therapy other than study drug unless there
was an absolute requirement, after which ESAs and
other therapies were permitted according to local prac-
tice if the Hb was <10 g/dL.
Assessment of renal function
Renal function was assessed by eGFR, with values
calculated locally and provided by the study sites
using the MDRD-4 formula [26]. Estimated GFR was
recorded at baseline and at every 3 months through-
out the 12-month study period. The change in eGFR
from baseline to the end of the study was a pre-
specified secondary endpoint of the trial. GFR was
estimated by the MDRD-4 formula [26]. As a post
hoc sensitivity analysis, GFR was also estimated by
the creatinine-based Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) formula [27]. CKD-
EPI values were calculated centrally using locally-
measured serum creatinine levels. The percentage of
patients starting dialysis was a further pre-specified
secondary endpoint.
Statistical analysis
All analyses of renal function were exploratory. Analysis
of covariance (ANCOVA) modeling was used to
compare the change in eGFR values from baseline to
month 12 between groups based on least square (LS)
mean values using a repeated fixed effects model with
treatment, visit and pooled country as factors, baseline
eGFR as covariate, and treatment-by-visit as an inter-
action. Change in eGFR at month 12 was summarized in
subpopulations of patients according to age (≤ or >
median), gender, body mass index (BMI, ≤ or > median),
baseline systolic and diastolic blood pressure (≤ or > me-
dian), mean arterial pressure and history of diabetes at
baseline. Furthermore, a multivariate analysis including
demographics and baseline characteristics (age, gender,
BMI, systolic and diastolic blood pressure, diabetic
status, prior use of angiotensin converting enzyme
[ACE] inhibitor and angiotensin II receptor blocker
[ARB] medications) was performed to check for poten-
tial confounding effect and best impacting factor on the
analysis of treatment effect.
For the proportion of patients requiring dialysis, logis-
tic regression analyses were performed and odds ratios
(ORs) were used to compare treatment groups.
Post hoc, absolute eGFR values and the change in eGFR
from baseline to month 12 were analyzed according to (i)
quartiles of total FCM dose throughout the 12-month
study using pooled data from both FCM treatment groups
(ii) quartiles of change in ferritin level from baseline to
month 12 across all patients (iii) quartiles of change in
TSAT level from baseline to month 12 across all patients.
Renal function was analyzed in the intention-to-treat
(ITT) population, comprising all patients who received
at least one dose of randomized treatment and who
attended at least one post-baseline visit. Patients were
excluded from the analysis of change in eGFR to month
12 if (a) they reached the primary event before month
12 (i.e. received alternative management for anemia) or
(b) the randomized treatment regimen was permanently
discontinued before month 12. Within this cohort,
calculations for the change in eGFR, ferritin and TSAT
from baseline to month 12 were based on the sub-
populations of patients who had values available at
both time points.
Adverse events were analyzed in the safety population,
comprising all patients who received at least one dose of
randomized study drug.
All statistical analyses were performed using SAS




In total, 613 patients were randomized and included in
the ITT population. Estimated GFR was measured at
baseline in all patients. Of 519 patients who completed
the study, 166 patients had started another anemia
management and/or stopped the randomized study regi-
men before month 12, and were excluded from analyses.
Thus eGFR values at both baseline and month 12 were
analyzed in 353 patients (97, 89 and 167 patients in the
high ferritin FCM group, the low ferritin FCM group
and the oral iron group, respectively). These patients
were included in the current analysis. The demographics
and other characteristics of this subpopulation (Table 1)
did not differ from the total ITT population (Additional
file 1: Table S1) and were comparable between groups.
Baseline eGFR in this subpopulation of patients was
similar between treatment groups (Table 2) and did not
show any relevant differences to baseline values in
the total ITT population (mean [SD] 32.8 [11.7] mL/
min/1.73 m2, 31.5 [10.7] mL/min/1.73m2and 32.3
[11.6] mL/min/1.73 m2, respectively, in the high fer-
ritin FCM, low ferritin FCM and oral iron groups).
Four patients in this cohort of 353 patients were included
against protocol with baseline eGFR >60 mL/min/1.73 m2:
one high ferritin FCM patient (63 mL/min/1.73 m2), one
low ferritin FCM patient (61 mL/min/1.73 m2) and two
patients in the oral iron group (66 and 77 mL/min/
1.73 m2). Three patients in the oral iron group contravened
the exclusion criterion that eGFR loss was to be no more
than 12 mL/min/1.73 m2 per year.
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Change in renal function
Values for eGFR showed no change in any of the three
treatment groups throughout the 12-month study
(Fig. 1). At month 12, mean (SD) eGFR was 35.6 (13.8)
mL/min/1.73 m2, 32.1 (12.7) mL/min/1.73 m2 and 33.4
(14.5) mL/min/1.73 m2, respectively. The pre-defined
endpoint of change from baseline to month 12 was +0.7
(0.9) mL/min/1.73 m2 in the high ferritin FCM group,
-0.9 (0.9) mL/min/1.73 m2 in the low ferritin FCM group
and -0.9 (0.7) mL/min/1.73 m2 in the oral iron group
(least square [LS] mean [SE] values). There were no sig-
nificant differences in the change from baseline to
month 12 for either FCM group versus oral iron (p =
0.15 for the high ferritin group, p = 0.99 for the low fer-
ritin FCM group). The mean (SE) percentage change in
eGFR was 3.1 (2.6)% in the high ferritin FCM group (p
= 0.098 versus oral iron) (Table 2).
As a sensitivity analysis, eGFR was also calculated
using the CKD-EPI formula. Serum creatinine values
were provided for central calculation of CKD-EPI
values in 82, 68 and 137 patients in the high ferritin
FCM, low ferritin FCM and oral iron groups, respect-
ively. Based on the CKD-EPI formula, there was a
significant increase in eGFR from baseline to month
12 for the high ferritin FCM group versus oral iron
(p = 0.012) (Table 2).
When the change in eGFR from baseline to month 12
was assessed in subpopulations of patients according to
age, gender, BMI, presence/absence of diabetes, systolic
and diastolic blood pressure and mean arterial pressure,
no apparent influence of treatment group was observed
(Additional file 2: Table 2).
Change in renal function according to FCM dose
The mean (SD) total dose of FCM 2793 (932) mg
iron in the high ferritin group and 1205 (626) mg
iron in the low ferritin group among patients with
eGFR data available at baseline and month 12 (ex-
cluding patients who started another anemia therapy
or permanently discontinued study treatment.) The
change in eGFR from baseline to month 12 showed
Table 1 Baseline characteristics for patients with eGFR values at
baseline and month 12
High ferritin
FCM (n = 97)
Low ferritin
FCM (n = 89)
Oral iron
(n = 167)
Age, years 69.3 (12.9) 69.0 (12.1) 69.6 (12.7)
Female gender, n (%) 61 ((62.9) 56 (62.9) 106 (63.5)
White race, n (%) 93 (95.9) 83 (93.3) 159 (95.2)
Body mass index, kg/m2 30.5 (6.8) 30.0 (5.3) 29.4 (5.4)
History of diabetes, n (%) 61 (62.9) 59 (66.3) 106 (63.5)
Endogenous
erythropoietin, mIU/mL
29.4 (24.6) 29.6 (27.4) 26.3 (20.9)
Hb, g/dL 10.4 (0.7) 10.5 (0.9) 10.7 (0.6)
Ferritin, μg/L 54.2 94.9) 45.8 (44.3) 52.4 (39.9)
TSAT, % 16.3 (20.2) 14.9 (7.5) 14.8 (7.0)
C-reactive protein, mg/L 7.4 (13.4) 5.7 (5.9) 5.3 (6.5)
ACE inhibitor therapy
prior to study entry,
n (%)a
32 (33.0) 37 (41.6) 69 (41.3)
Angiotensin II antagonist
therapy prior to study
entry, n (%)b
41 (42.3) 33 (37.1) 77 (46.1)
Continuous variables are shown as mean (SD)
ACE angiotensin converting enzyme inhibitor, FCM ferric carboxymaltose, Hb
hemoglobin, TSAT transferrin saturation
aIncludes patients receiving ACE inhibitor combinations
bIncludes patients receiving angiotensin II antagonist combinations
Table 2 Estimated GFR (eGFR) for patients with eGFR values at
baseline and month 12
High ferritin
FCM (n = 97)
Low ferritin
FCM (n = 89)
Oral iron
(n = 167)
eGFR at baseline (MDRD),
mL/min/1.73 m2
Mean (SD) 34.9 (11.3) 32.8 (10.8) 34.2 (12.3)
≥ 60, n (%) 1 (1.0) 1 (1.1) 3 (1.8)
30 to <60, n (%) 62 (63.9) 51 (57.3) 101 (60.5)
15 to <30, n (%) 34 (35.1) 37 (41.6) 60 (35.9)
< 15, n (%) 0 0 3 (1.8)
eGFR at month 12 (MDRD),
mL/min/1.73 m2
Mean (SD) 35.6 (13.8) 32.1 (12.7) 33.4 (14.5)
≥ 60, n (%) 7 (7.2) 4 (4.5) 7 (4.2)
30 to <60, n (%) 54 (55.7) 40 (44.9) 83 (49.7)
15 to <30, n (%) 32 (33.0) 39 (43.8) 65 (38.9)
< 15, n (%) 4 (4.1) 6 (6.7) 12 (7.2)
Change from baseline to
month 12, LS mean (SE)
(MDRD), mL/min/1.73 m2
0.7 (0.9) -0.9 (0.9) -0.9 (0.7)
p value for change vs oral irona 0.15 0.99 Reference
Relative change from baseline
to month 12, LS mean (SE)
(MDRD), %
3.1 (2.6) -2.4 (2.7) -2.2 (2.0)
p value for change vs oral irona 0.098 0.95 Reference
eGFR (CKD-EPI)
mL/min/1.73 m2
n = 82 n = 68 n = 137
Mean (SD) at baseline 33.5 (11.9) 32.0 (11.8) 32.5 (13.4)
Mean (SD) at month 12 34.8 (13.1) 31.1 (13.5) 31.0 (14.8)
Change, LS mean (SE),
mL/min/1.73 m2
1.3 (1.0) -1.2 (1.0) -1.7 (0.7)
p value for change vs oral irona 0.012 0.68 Reference
eGFR was estimated by the MDRD-4 equation [27] at the local laboratory
CI confidence interval, CKD-EPI Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI), eGFR estimated GFR, FCM ferric carboxymaltose, LS
least squares, MDRD Modification of Diet in Renal Disease, SE standard error
aAnalysis of covariance analysis based on least square mean values, using
repeated measures
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no association with total FCM dose when plotted in-
dividually for patients in either the high ferritin FCM
or low ferritin FCM groups (Additional file 3: Figure S1).
Using pooled data from both FCM groups, the change in
eGFR to month 12 was analyzed by quartiles of total FCM
dose (Fig. 2a).
The multivariate model indicated that age (p = 0.007),
systolic blood pressure (p = 0.004), diabetic status (p =
0.058) and prior use of ACE inhibitor therapy (p = 0.054)
exerted an impact on the change in eGFR (MDRD) to
month 12. When these factors were added into the
repeated measures model over time, the least square
mean values for treatment effect were similar for the
high ferritin FCM, low ferritin FCM and oral iron
groups (0.7, -0.8 and -0.9 mL/min/1.73 m2, respectively;
p = 0.14 for high ferritin FCM versus oral iron, p = 0.92
for low ferritin FCM versus oral iron). When repeated
using the CKD-EPI equation to estimate GFR, only age
(p = 0.042) and systolic blood pressure (p = 0.004) were
found to influence the change in eGFR to month 12.
Inclusion of these two factors in the repeated measure
model produced LS mean values of 1.3 mL/min/1.73 m2
for the high ferritin FCM group, -1.1 mL/min/1.73 m2
for the low ferritin FCM group and -1.7 mL/min/
1.73 m2 for the oral iron group (p = 0.010 versus high
ferritin FCM, p = 0.613 versus low ferritin FCM).
Change in renal function according to iron status
Mean ferritin levels were within the pre-specified target
ranges from week 12 to the end of the study in both of
the FCM treatment arms (Additional file 4: Figure S2a).
At month 12, the mean (SD) change in ferritin from
baseline was 455 (116), 81 (59) and 139 (111) μg/L in
the high ferritin FCM, low ferritin FCM and oral iron
groups, respectively, among patients with eGFR available
at baseline and month 12. The change in eGFR from
baseline to month 12 showed no significant association
with the change in ferritin over the same period when
analyzed by quartiles (Fig. 2b).
TSAT levels to month 12 are shown in Additional file 4:
Figure S2b. As observed for ferritin levels, the change in
eGFR showed no significant differences between quartiles
of change in TSAT (Fig. 2c).
Renal events
In total, 16/613 patients in the ITT population (2.6%)
progressed to dialysis by month 12 (5 high ferritin FCM,
1 low ferritin FCM, 10 oral iron). There was no signifi-
cant difference in the risk of dialysis for either FCM
group versus oral iron: OR 1.01 (95% CI 0.34, 3.00; p =
0.99) for the high ferritin FCM group and OR 0.20 (95%
CI 0.03, 1.56; p = 0.12) for the low ferritin group. No pa-
tient underwent renal transplantation.
Rates of adverse events and serious adverse events
related to renal function were low with no indication of
clinically relevant differences between treatment groups
(Additional file 5: Table S3).
Discussion
Results from the randomized FIND-CKD trial show that
compared to oral iron, administration of IV FCM in
doses that maintain ferritin levels of 100–200 μg/L or
Fig. 1 Estimated GFR to month 12 according to treatment group in patients with eGFR values at baseline and month 12. Values are shown as
mean (SD). FCM, ferric carboxymaltose; eGFR, estimated GFR
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400–600 μg/L does not negatively impact renal function,
as determined by eGFR, in patients with ND-CKD after
1 year. Mean eGFR remained stable during the study in
both the FCM treatment groups, and the change in
eGFR to 1 year did not differ from that seen in patients
treated with oral iron therapy, either on univariate or
multivariate analysis. These findings, calculated using
the pre-specified MDRD-4 formula, were confirmed when
GFR was estimated by the more recently developed CKD-
EPI formula [28]. Indeed, if anything, there was an in-
crease in eGFR in the patients in the high-ferritin FCM
arm compared to oral iron using the CKD-EPI for-
mula (p = 0.012) which was confirmed on multivariate ana-
lysis. There was no difference between groups in the rate of
progression to dialysis and no evidence of increased renal
adverse events in either FCM treatment group.
Clinical studies measuring the short- or long-term
effect of IV iron complexes on renal function versus
controls are relatively scarce. Van Wyck et al.
randomized 188 patients with ND-CKD to a total dose
of 1000 mg iron as iron sucrose (infused over 3.5–4 h)
or oral iron sulfate [10]. At the end of the 6-week study,
there was a mean decrease in eGFR in both treatment
arms, but the decrease was smaller in the iron sucrose
arm (-1.45 mL/min/1.73 m2 versus -4.40 mL/min/
1.73 m2 in the oral iron arm; p = 0.01). McMahon et al.
undertook a randomized trial of iron sucrose (100–
200 mg every two months) or oral iron sulfate for
12 months in patients with ND-CKD who were non-
anemic (Hb ≥11 g/dL) and iron replete (ferritin >300 μg/
L and TSAT >25%) at baseline, and has described a simi-
lar change in eGFR in both treatment groups over the
study period [29]. This similarity was observed despite
elevated iron indices in the IV iron group at month 12
(mean ferritin 363 μg/L versus 125 μg/L in the oral iron
group; TSAT 30% versus 21%). However, the study ana-
lyzed only 85 patients, such that a relatively small effect
on renal function may have remained undetected, and
Fig. 2 Absolute estimated glomerular filtration rate (eGFR) and change in eGFR from baseline to month 12 according to quartiles of (a) total ferric
carboxymaltose (FCM) dose to month 12 in patients randomized to high ferritin FCM or low ferritin FCM (b) change in ferritin from baseline to month
12 across all treatment groups and (c) change in transferrin saturation (TSAT) from baseline at month 12 across all treatment groups. Data are shown
for patients with eGFR values at baseline and month 12. Change in eGFR is shown as least squares (LS) mean values. MDRD, Modification of Diet in
Renal Disease
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the study protocol specified only modest doses of iron
supplementation in both the IV and oral iron groups
(the actual amount administered was not specified).
Lastly, a recent randomized trial of IV iron sucrose ver-
sus oral iron showed no change in measured GFR over
2 years’ follow-up between the two arms of the study
[24]. Other randomized trials comparing IV iron versus
oral iron have not reported renal function, but there was
no evidence of a higher rate of renal adverse events in
the IV iron groups versus patients receiving oral iron
therapy [7–9, 11].
Regarding a possible effect of IV iron on proteinuria,
in a blinded, randomized, placebo-controlled cross-over
study of eight patients with ND-CKD, Leehey et al.
assessed the effect of a single dose of ferric gluconate at
a dose of 125 mg iron infused over one hour, or 250 mg
iron over two hours [21]. They observed no evidence of
acute renal injury, as assessed by albuminuria, protein-
uria or enzymuria, although plasma levels of the oxida-
tive stress marker malondialdehyde (MDA) increased
with both doses. Another randomized trial, by Agarwal
and colleagues, administered a single dose of 100 mg
iron sucrose to 20 subjects with CKD stage 3 or 4, and
also found an increase in MDA versus controls, accom-
panied by transient proteinuria and enzymuria which
resolved within 24 h [22]. Similar analyses have been
performed in repeated dose studies. In a multicenter,
randomized trial, 62 patients with ND-CKD and iron de-
ficiency anemia received a weekly dose of either iron su-
crose or ferric gluconate (100 mg) for 5 weeks [19].
Basal levels of proteinuria were similar, but increased
post-dosing, with a greater increase with iron sucrose
than ferric gluconate [19]. This was consistent with re-
sults from an earlier single-dose study from the same
group which showed that a single dose of iron sucrose
(100 mg) provoked a significantly higher urinary protein
to creatinine ratio than ferric gluconate [20]. The differ-
ence between iron sucrose and ferric gluconate is some-
what unexpected, since the latter is considered to be less
stable. Other authors have reported that rapid infusion
(5 min) of iron dextran or iron sucrose results in gener-
ation of reactive oxygen species [15], whereas a study of
20 iron-replete dialysis patients found that slow infusion
(60 min) of these preparations did not affect biomarkers
of oxidative stress or inflammation [30] (neither study
measured renal function). Finally, in the prospective RE-
VOKE trial [24], which was designed to detect renal tox-
icity of IV iron, proteinuria was similar in the IV iron
sucrose and oral iron arms.
In the current study, FCM-treated patients received an
initial single dose of up to 1000 mg iron in the high fer-
ritin group, or 200 mg in the low ferritin group (each in-
fused over 15 min), with mean total doses of ~2800 mg
iron and ~1200 mg iron, respectively, among patients
with eGFR data available at baseline and month 12. A
post hoc analysis indicated that within this range, there
was no association between quartiles of FCM dose and
the change in eGFR during the 12 months after the start
of FCM therapy. Moreover, neither absolute levels of fer-
ritin (a marker for iron stores) nor TSAT (a marker for
iron availability) at month 12, nor the change in ferritin
or TSAT during the study, showed an association with
change in eGFR. Thus, the significant increase in ferritin
levels achieved in the cohort of patients randomized to
high ferritin FCM was not associated with a change in
renal function.
Conclusions
The main limitation of these findings is the 1-year dur-
ation of the FIND-CKD trial which, while longer than
most previous comparative studies of IV versus oral iron
[7–11, 24], may not be adequate to detect a long-term
effect on renal function. Within the full study cohort, we
restricted the analysis to the patients who remained on
the randomized study drug for the full 12-month study;
any patient in whom another anemia therapy was intro-
duced or who discontinued the study prematurely was
excluded. While this reduced the population size, we be-
lieve that this was the most rigorous analytical approach.
No patient discontinued the study due to decreasing
renal function so bias due to selective discontinuation
can be ruled out. Moreover, baseline and month 12
values for eGFR (and the extent of change from baseline
to month 12) were similar in each treatment group to
those seen in the full ITT population [25]. A post hoc re-
peated measured modeling calculation showed that the
population analyzed here (n = 353) had a 15 and 18%
power, respectively, to detect a difference of 1.0 ml/min/
1.73 m2 in the change in eGFR between the high and
low ferritin FCM groups, and between the high ferritin
FCM and oral iron groups (40 and 49%, respectively, to
detect a difference of 2 mL/min/1.73 m2). The study
used eGFR as the indicator of renal function rather than
a method to measure GFR. Furthermore, GFR estimates
were based on locally determined serum creatinine
values, so that variability between methods at different
sites cannot be excluded. It is unlikely, however, that
such variations would have obscured differences between
treatment groups, since each patient served as their own
control at baseline using the same assay. Another limita-
tion is that urinary protein excretion and biomarkers of
renal tubular toxicity were not recorded. Also, patients
previously showing a rapidly progressive loss of renal
function at screening were excluded from the study. In-
deed, it is remarkable that the annual loss of eGFR was
no more than 1.6 mL/min/1.732 in any group. Other eli-
gibility criteria for the study may have contributed to
this stability, notably exclusion of patients with previous
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eGFR loss >12 mL/min/1.73 m2/year but also, for ex-
ample, those with poorly controlled hypertension. More-
over, approximately three-quarters of patients were
receiving an ACE inhibitor or an angiotensin II receptor
antagonist. Lastly, in terms of the study design, the ab-
sence of a placebo arm precludes a comparison of renal
function using IV iron versus no treatment and would
have contributed to understanding if the observed stabil-
ity of renal function was partly a trial effect.
In conclusion, results from this study indicate a lack of
renal toxicity of IV iron therapy in patients with relatively
stable renal function. It is important to note that these re-
sults do not necessarily apply to other IV iron preparations,
due to varying molecular structures and physiochemical
properties, or to patients with other characteristics (for ex-
ample those receiving dialysis). Assessment of longer-term
effects of IV iron, however, is required.
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Paul E Stevens (Canterbury), Mohsen El Kossi (Doncaster),
Simon Roe (Nottingham), Brian Camilleri (Ipswich),
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SA 5O65
Australia 0102 Bellberry HREC 229 Greenhill Road Dulwich
SA 5O65
Australia 0103 Hunter Area Research Ethics Committee John
Hunter Hospital Lookout Road
New Lambton Heights NSW 23O5
Australia 0104 Research Ethics Committee Royal Adelaide
Hospital North Terrace
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Australia 0105 Human Research Ethics Committee Royal
Melbourne Hospital Parkville, Victoria 3O5O
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Princess Alexandra Hospital Ispswich Road
Woolloongabba, QLD 4fO2
Australia 9 Ballarat Health Services and St. John of God
Health Care Ethics Committee
Base Hospital Drummond Street North PO
Box 577 Ballarat 3353
Australia 0110 Hunter Area Research Ethics Committee John
Hunter Hospital Lookout Road
New Lambton Heights NSW 2305
Australia 0111 Hunter Area Research Ethics Committee John
Hunter Hospital Lookout Road
New Lambton Heights NSW 2306
Australia 0111 Royal Brisbane and Women’s Hospital HREC
University of Queensland, Centre for Clinical
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Hospital Avenue Nedlands, WA 6009
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Wellington Street, WA 6000
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Australia 0119 Hunter Area Research Ethics Committee
John Hunter Hospital Lookout Road
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Austria 0203 Ethikkommission der Stadt Wien Town Thomas-
Klestil-Platz 8/2 A-1030 Wien, Osterreich




Austria 0205 Ethikkommission Krankenhaus der Elisabethinen
Linz GmbH Fadingerstrasse 1
A-4 Linz Osterreich
Austria 0206 Ethikkommission der Medizinischen Universitat
Innsbruck Innrain 43
A-6020 Innsbruck Osterreich
Austria 0207 EK des Landes Oberosterreich Landesnervenklinik
Wagner-Jauregg Strasse Wagner-Jauregg Weg 15
A-4020 Linz Osterreich
Belgium 0301 Secretariaat Ethische Commissie UZ Gent Attn.
Prof. Dr Matthys De Pintelaan 185
9000 Gent
Belgium 0302 H.-Hartziekenhuis Roeselare-Menen vzw Attn. Dr.
Ludo Marcelis WILGENSTRAAT 2
8800 ROESELARE
Belgium 0303 Dr Van Vlem
Onze-Lieve-Vrouwziekenhuis Attn. Greet de Geest
Moorselbaan 164 9300 Aalst
Belgium 0304 Commissie Medische Ethiek van Universitaire
Ziekenhuizen K.U.Leuven Attn. Prof. Walter Van
den Bogaert
Campus Gasthuisberg E330 Herestraat 49
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Belgium 0305 Kristien Schoenmakers gang beheer en directie
ZOL Campus St Jan Schiepse bos 6 3600 Genk
Belgium 0306 Hopitaux IRIS Sud-site Joseph Bracops Rue
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Belgium 0307 Comité d’Ethique du Epicura Ath-Baudour Attn.
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136 rue Louis Caty 7331 Baudour
Belgium 0308 Commission d’Ethique Biomédicale Hospitalo-
Facultaire Attn. Pr Jean-Marie Maloteaux Cliniques
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0401 Etická komise IKEM a FN Thomayerovy s
poliklinikou
Vídeňská 800 140 59 Praha 4
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0402 Etická komise pro multicentrická hodnocení
Fakultní nemocnice v Motole V Úvalu 84,
150 06 Praha 5
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0403 Etická komise Litomyšlská nemocnice
a.s. J. E. Purkyně 652 570 14 Litomyšl
Czech
Republic
0404 Etická komise Nemocnice Jihlava
Vrchlického 59 586 01 Jihlava
Czech
Republic
0405 Etická komise pro multicentrická hodnocení
Fakultní nemocnice v Motole V Úvalu




Krajská nemocnice T. Bati a.s. Zlín Havlíčkovo
nábřeží 600 762 75 Zlín
Czech
Republic
0407 Etická komise Fakultní nemocnice Hradec
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Čapka 589 397 23 Písek
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0409 Etická komise Nemocnice Tábor, a.s. Kpt.
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FN Brno Bohunice Jihlavská 20 625 00 Brno
Czech
Republic
0412 Etická komise B. Braun Avitum Bulovka
Budínova 67 181 02 Praha 8
Czech
Republic
0413 Etická komise B. Braun Avitum Bulovka
Budínova 67 181 02 Praha 8
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Republic
0414 Etická komise Nemocnice s poliklinikou
v Novém Jičíně, p.o.
K Nemocnici 775/76 741 01 Nový Jičín
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0415 Etická komise B. Braun Avitum Bulovka
Budínova 67 181 02 Praha 8
Czech
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0416 Etická komise Nemocnice Znojmo MUDr.
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Czech
Republic
0417 Etická komise B. Braun Avitum Bulovka
Budínova 67 181 02 Praha 8
Czech
Republic
0418 Etická komise společnosti Fresenius Medical
Care - DS, s.r.o.
Lužná 591
160 05 Praha 6
Czech
Republic
0419 Etická komise pro multicentrická hodnocení
Fakultní nemocnice v Motole V Úvalu 84
150 06 Praha 5
Czech
Republic
0420 Etická komise společnosti Fresenius Medical
Care - DS, s.r.o.
Lužná 591
160 05 Praha 6
Czech
Republic
0421 Etická komise společnosti Fresenius Medical
Care - DS, s.r.o.
Lužná 591
160 05 Praha 6
Czech
Republic
0422 Etická komise společnosti Fresenius Medical
Care - DS, s.r.o.
Lužná 591
160 05 Praha 6
Czech
Republic
0423 Etická komise společnosti Fresenius Medical
Care - DS, s.r.o.
Lužná 591
160 05 Praha 6
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0424 Etická komise pro multicentrická hodnocení
Fakultní nemocnice v Motole V Úvalu 84,
150 06 Praha 5










Denmark 0503 De Videnskabsetiske Komiteer for Region
Hovedstaden
Regionsgården Kongens Vænge 2 DK-3400
Hillerød

















France 0602 CPP Sud-Méditerranée IV Dr Alain DUBOIS
Hôpital Saint Eloi Rue Bertin Sans 34295
Montpellier Cedex 5
France 0603 CPP Sud-Méditerranée IV Dr Alain DUBOIS
Hôpital Saint Eloi Rue Bertin Sans 34295
Montpellier Cedex 5
France 0604 CPP Sud-Méditerranée IV Dr Alain DUBOIS
Hôpital Saint Eloi Rue Bertin Sans 34295
Montpellier Cedex 5
France 0605 CPP Sud-Méditerranée IV Dr Alain DUBOIS
Hôpital Saint Eloi Rue Bertin Sans 34295
Montpellier Cedex 5
France 0606 CPP Sud-Méditerranée IV Dr Alain DUBOIS
Hôpital Saint Eloi Rue Bertin Sans 34295
Montpellier Cedex 5
France 0607 CPP Sud-Méditerranée IV Dr Alain DUBOIS
Hôpital Saint Eloi Rue Bertin Sans 34295
Montpellier Cedex 5
France 0608 CPP Sud-Méditerranée IV Dr Alain DUBOIS
Hôpital Saint Eloi Rue Bertin Sans 34295
Montpellier Cedex 5
France 0609 CPP Sud-Méditerranée IV Dr Alain DUBOIS
Hôpital Saint Eloi Rue Bertin Sans 34295
Montpellier Cedex 5
France 0610 CPP Sud-Méditerranée IV Dr Alain DUBOIS
Hôpital Saint Eloi Rue Bertin Sans 34295
Montpellier Cedex 5
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France 0611 CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital
Saint Eloi Rue Bertin Sans 34295 Montpellier
Cedex 5
France 0612 CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital
Saint Eloi Rue Bertin Sans 34295 Montpellier
Cedex 5
Germany 0701 Ethik-Kommmission bei der Medizinischen Fakultät
der Universitat Wurzburg Institut für Pharmakologie
und Toxikologie Versbacher Str. 9
97078 Wurzburg Wuerzburg
Germany 0702 Site 0702
Ethik-Kommission der Arztekammer Hamburg
Humboldtstr. 67a 22083 Hamburg
Germany 0703 Site 0703
Wthikkommission an der Medizinischen Fakultat
Ernst-Moritz-Arndt-Universitat Greifswald Institut
fur Pharmakologie
Friedrich-Loeffler-Str. 23d 17487 Greifswald
Germany 0704 Site 0704, 0721
Ethikkommission der Arztekammer Nordrhein
Tersteegenstr. 9
40474 Dusseldorf
Germany 0705 Site 0705, 0708, 0710, 0711
Ethikkommission der Arztekammer Westfalen-Lippe
und der Medizinischen Fakultat der WWU-Munster
Von-Esmarch-Strasse 62
48149 Munster
Germany 0706 Site 0706
Ethikkommission der Universitat Ulm
Helmholtzstrasse 20
(Oberer Eselsberg) 89081 Ulm
Germany 0708 Site 0705, 0708, 0710, 0711
Ethikkommission der Arztekammer Westfalen-Lippe
und der Medizinischen Fakultat der WWU-Munster
Von-Esmarch-Strasse 62
48149 Munster
Germany 0709 Site 0709, 0729
Ethik-Kommission der Landesarztekammer Hessen
Im Vogelsang 3
60488 Frankfurt am Main
Germany 0710 Site 0705, 0708, 0710, 0711
Ethikkommission der Arztekammer Westfalen-Lippe
und der Medizinischen Fakultat der WWU-Munster
Von-Esmarch-Strasse 62
48149 Munster
Germany 0711 Site 0705, 0708, 0710, 0711
Ethikkommission der Arztekammer Westfalen-Lippe
und der Medizinischen Fakultat der WWU-Munster
Von-Esmarch-Strasse 62
48149 Munster
Germany 0712 Site 0712, 0726
Ethik-Kommission der Bayerischen
Landesarztekammer Muhlbaurstrasse 16 81677
Munchen
Germany 0713 Site 0713, 0725
Landesamt fur Gesundheit und Soziales
Geschaftsstelle der Ethik-Kommission des
Landes Berlin Fehrbelliner Platz 1
10707 Berlin
Germany 0714 Site 0714, 0722
Ethikkommission Landesarztekammer
Rheinland-Pfalz Deutschhausplatz 3 55116 Mainz
Table 3 FIND-CKD trial: Ethics Committee approvals (Continued)
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Germany 0716 Site 0716
Ethik-Kommission des Fachbereichs Medizin der
Johann Wolfgang Goethe- Universitat Haus 1
Theodor-Stern-Kai 7
60590 Frankfurt
Germany 0717 Site 0717, 0730
Ethik-Kommission bei der Landesarztekammer
Baden-Wurttemberg Jahnstr. 40 70597 Stuttgart
Germany 0719 Site 0719
Ethikkommission bei der Arztekammer
Niedersachsen zur Beurteilung Medizinischer
Forschung am Menschen Berliner Allee 20
30175 Hannover
Germany 0720 Site 0720
Ethikkommission bei der Sachsischen
Landesarztekammer Schutzenhohe 16
99 Dresden
Germany 0721 Site 0704, 0721
Ethikkommission der Arztekammer Nordrhein
Tersteegenstr. 9
40474 Dusseldorf
Germany 0722 Site 0714, 0722
Ethikkommission Landesarztekammer
Rheinland-Pfalz Deutschhausplatz 3 55116 Mainz
Germany 0724 Site 0724
Ethik-Kommission der Otto-von-Guericke-
Universitat an der Medizinischen Fakultat
Leipziger Str. 44 39120 Magdeburg
Germany 0725 Site 0713, 0725
Landesamt fur Gesundheit und Soziales
Geschaftsstelle der Ethik-Kommission des
Landes Berlin Fehrbelliner Platz 1
10707 Berlin





Germany 0727 Site 0727
Ethik-Kommission der Universitat Witten/
Herdecke Alfred-Herrhausen-Str. 50
58448 Witten
Germany 0728 Site 0728









60488 Frankfurt am Main
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Greece 0801 Ethical Committee
General University Hospital of Thessaloniki
“Papgeorgiou” Thessaloniki Ring Road, Nea
Efkarpia Thessaloniki, 56429
Greece 0802 General Hospital of Thessaloniki “Ippokrateion”
49 Konstantinoupoleos st. Thessaloniki, 56442
Greece 0803 ATTIKON General University Hospital of Athens
1 Rimini Str.
Chaidari, Athens, 12462
Greece 0804 General University Hospital of Alexandroupolis
Dragana Alexandroupolis, 68100
Greece 0805 Ethical Commitee
General University Hospital of Larissa Mezourlo
Larissa, 41110
Greece 0806 Ethics Committee
Achillopoulio General Prefecture Hospital of
Volos 134 Polyeri street
Volos, 38222
Greece 0807 Ethical Commitee
General Hospital of Rhodes Aghioi Aphostoloi
Rhodes, 85100
Greece 0808 Ethical Commitee
IPPOKRATEION General Hospital of Athens 114
Vas. Sofias Ave Athens, 11526
Greece 0809 Ethical Commitee
General Hospital of Athens, KORGALENEIO-
BENAKEIO Athenasaki Str. 1
Athens, 11526
Greece 0810 Ethical Commitee
General Prefecture Hospital of Ioannina,
XATZIKOSTA Avv. Makrigianni 1
Ioannina, 45550
Greece 0811 Ethical Commitee
General University Hospital of Patras Rio-Patras
Street Rios Patras, 16500
Greece 0812 Ethical Commitee
General University Hospital of Ioannina Stavros
Niarchos Avenue Ioannina, 45550
Greece 0813 Ethical Commitee General Hospital of Arta
A. Zara Str 4 Arta, 47100
Greece 0815 Ethical Commitee
General Hospital of Peireus “Tzaneio” Zanni &
Afendouli Peireus, 18536
Greece 0817 Ethical Commitee
General Prefecture Hospital of Argos 191
Korinthou Str.
Argos, 21200
Greece 0818 Ethical Commitee
LAIKO General Hospital of Athens 17 Aghiou
Thomas Str.
Athens, 11527
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Greece 0819 Ethical Commitee
General Hospital of Mytilene “Vostanio” 48 E.
Vostani Str.
Vestos, 81100
Greece 0820 Ethical Commitee General Hospital of Serres 2nd
k of Serres-Drama National Road Serres, 62100
Greece 0821 Ethical Commitee
KYANOUS STAVROS General Hospital of Athens
102, Vas Sofias Ave Athens, 11528
Greece 0822 Ethical Commitee
IASO General Hospital of Athens Cholargos
Athens, 11526
Greece 0823 Ethical Commitee
General Hospital of Athens “Henry Dunant” 107
Messogheion Ave Athens, 11526
Italy 1001 Comitato Etico
Dell’Azienda Ospedaliera di Lecco Via Dell’Eremo
9/11 Lecco, 23900
Italy 1002 Comitato Etico Locale per la Sperimentazione
Clinical Della AUSL 12 di Viareggio Via Aurelia 335
55045 Lido di Cà Maiore (LC)
Italy 1003 Comitato Etico Dell’Azeinda Ospedaliera
Universitaria Della Seconda Univestità degli
Studi di Napoli Via Costatinopoli, 104
80138 Napoli
Italy 1004 Comitato Etico Indipendente dell’Azienda
ospedaliero-Univesitaria Policlinico S. Orsola
Via Albertoni 15
40138 Bologna
Italy 1005 Comitato Etico Della ASL TO/2 di Torino Corso
Svizzera 185 bis 10149 Torino
Italy 1007 Comitato di Bioetica della Azienda Ospedali Riuniti
di Bergam Largo Barozzi 1
24128 Bergamo
Italy 1008 Comitato Etico ASL di Caserta Via Unità Italiana
28 81100 Caserta
Italy 1009 Comitato Etico Dell’Azienda Ospedaliera
Universitaria ‘S. Martin’ di Genova Largo Rosanna
Benzi 10 16132 Genova
Italy 1 Comitato Etico Della Provincia di Modena Via
Largo del Pozzo 71 41124 Modena
Italy 1011 Comitato Etico ASL CE/1 Di Caserta Via Unità
Italiana 28 81100 Caserta
Italy 1012 Comitato Etico Regionale Unico (CERU) AOU
Santa Maria della Misericordia Piazzale Santa
maria della Misericordia 15 33100 Udine
Italy 1013 Comitato Etico Scientifico Dell’Azienda Ospedaliera
Ospedale S. Carlo Borromeo di Milano
Via Pio II° n° 3 20153 Milano
Italy 1014 Comitato Bioetico Dell’Azienda Cannizzaro di
Catania Via Messina 829
95126 Catania
Italy 1016 Comitato Ethico-Scientifico Dell’Azienda
Ospedaliera Ospedale Niguara Ca’ Granda Di
Milano Piazza Ospedale Maggiore n. 3 20162 Milano
Italy 1017 Comitato Etico Della AUSL RM/H Di Albano Laziale
Borgo Garibaldi n. 12 00041 Albano Laziale (RM)
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Italy 1018 Comitato Etico Dell’Azienda Ospedaliera Pugliese-
Ciaccio Di Catanzaro
Via Vinicio Cortese, 10 88100 Catanzaro
Italy 1020 Comitato Etico Dell’Azienda Ospedaliera
Universitaria S. Giovanni Battista di Torino C
so Bramante 88/90 10126 Torino
Italy 1021 Comitato Etico Scientifico Dell’Azienda
Ospedaliera
Ospedale S. Carlo Borrome di Milano
Via Pio II°, n°3 20153 Milano
Italy 1022 Comitato Etico Central Dell’IRCCS Fondazione
Salvatore Maugeri Di Pavia Via Salvatore Maugeri
4 27100 Pavia
Italy 1023 Comitato Etico Sperimentazione clinical Medicinali
Della AUSL 8 Di Arezzo Via Curtatone 54
52100 Arezzo
Italy 1024 Comitato Etico
Azienda Ospedaliera Universitaria Ospedali Riuniti
di figgia
Viale Luigi Pinto 71100 Foggia
Italy 1026 Comitato di Etica Della ASL di Salerno Via Federico
Ricco, 50 84014 Noceria Inferiore (SA)
Italy 1027 Comitato Etico Per le Sperimentazioni Cliniche die
Medicinali Della Provincia di Venezia
Via Don Federico Tosatto 147 30174 Venezia
Italy 1028 Comitato Etico Della AUSL RM/G di Tivoli Via
Tiburtina 22/a 00019 Tivoli (RM)
Italy 1029 Comitato Etico Delle Aziende Sanitarie Dell’Umbria
di Perugia




1101 Meander Medical Center, Lichtenberg location
Toetsingscommissie Wetenschappelijk Onderzoek
Secretariat, P&O Room N042 Utrechtseweg 160
3818 ES Amersfoort The Netherlands
Netherlan
ds






1102 Medical Ethics Review Committee Gelre Hospital
Albert Schweitzerlaan 31
7334 DZ Apeldoorn The Netherlands
Netherlan
ds
1103 Medical Ethics Review Committee Gelre Hospital
Albert Schweitzerlaan 31
7334 DZ Apeldoorn The Netherlands
Netherlan
ds
1104 Medical Ethics Review Committee Albert Schweitzer
Hospital loc. DW, Postvak 7, kmr. Z 150
T.a.v. Ms. A. de Graag – de Vries Albert




1105 METc VU Medical Center Medical Faculty, Room




1106 Medical Ethics Review Committee Noord- Holland
Foreest Medical School Nassauplein 10 1815
GM Alkmaar The Netherlands
Norway 1201 Regional Committees for Medical and Health
Research Ethics (REK) REK-Midt
Bygg for samfunnsmedisin (5 etg) Håkon Jarlsgt.
11, St. Olavs Hospital Trondheim
Table 3 FIND-CKD trial: Ethics Committee approvals (Continued)
Poland 1301 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1302 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1303 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1306 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1309 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1311 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1313 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1314 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1315 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1316 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1318 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1320 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1321 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłod
owskiej-Curie 3a, 80-201 Gdańsk, Polska
Poland 1322 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1323 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
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Poland 1324 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1326 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1327 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1328 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1329 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1330 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Poland 1331 Niezależna Komisja Bioetyczna do Spraw Badań
Naukowych przy Gdańskim Uniwersytecie
Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201
Gdańsk, Polska
Portugal 1402 CEIC- National Ethics Committee for Clinical
Investigation Parque da Saúde de Lisboa- Avenida
do Brasil, 53 1749-004 Lisboa- Portugal
Portugal 1403 CEIC- National Ethics Committee for Clinical
Investigation Parque da Saúde de Lisboa- Avenida
do Brasil, 53 1749-004 Lisboa- Portugal
Portugal 1404 CEIC- National Ethics Committee for Clinical
Investigation Parque da Saúde de Lisboa- Avenida
do Brasil, 53 1749-004 Lisboa- Portugal
Portugal 1405 CEIC- National Ethics Committee for Clinical
Investigation Parque da Saúde de Lisboa- Avenida
do Brasil, 53 1749-004 Lisboa- Portugal
Portugal 1406 CEIC- National Ethics Committee for Clinical
Investigation Parque da Saúde de Lisboa- Avenida
do Brasil, 53 1749-004 Lisboa- Portugal
Portugal 1407 CEIC- National Ethics Committee for Clinical
Investigation Parque da Saúde de Lisboa- Avenida
do Brasil, 53 1749-004 Lisboa- Portugal
Spain 1501 Hospital Universitario Dr Peset de Valencia CEIC,
a/a Raquel E. Blesa, C/Juan de Garray 21, 1er Piso
Consultas externas, 46017 Valencia
Spain 1503 Hospital Universitario Dr Peset de Valencia CEIC,
a/a Raquel E. Blesa, C/Juan de Garray 21, 1er Piso
Consultas externas, 46017 Valencia
Spain 1504 CEIC Hospital Universitario La Paz(LEC) Paseo de la
Castellana, 261, Planta 8a Hospital General, 28046
Madrid
Spain 1505 CEIC Fundació Puigvert IUNA (LEC) Agencia de
Gestio del Coneixement Cartagena, 340-350 08025
Barcelona
Table 3 FIND-CKD trial: Ethics Committee approvals (Continued)
Spain 1506 CEIC Hospital Universitario General Gregorio
Marañón (CEC) CEIC Area 1, C/ dr Esquerdo, 46,
28007 Madrid
Spain 1507 Agencia de Ensayos Clinicos - servicio de Farmacia
Hospital Clinic de Barcelona, c/ Villarroel, 170 -
Sotano, Escalera 6b, 08036 Barcelona
Spain 1509 CEIC Hospital Universitario de Bellvitge Edificio
Consultas Externas. Planta -1, C/ Feixa Llarga, s/n,
08907 L’Hospitalet de Llobregat, Barcelona
Spain 1510 CEIC Hospital Universitari Vall d'Hebron Edifici
Institut de Recerca, 2a planta Passeig Vall d’Hebron
119-129, Barcelona 08035
Spain 1512 CEIC Hospital Universitario Fundación de Alcorcón
(LEC) C/ Budapest N1, 28922 Alcorcon, Madrid
Spain 1513 CEIC Clinica de Asturias
Hospital Central de Asturias, Celestino Villamil, s/n,
33006 Oviedo
Spain 1514 Hopsital Universitario “Reina Sofia” Comite Etico de
Ensayos Clinicos, Edificio de Consultas Externas,
planta -1, Avda. Menendez Pidal, s/n, 14004 Cordoba
Spain 1515 Hospital Torrecardenas CEIC
Paraje Torrecardenas, s/n, 04009 Almeria
Spain 1516 Fundacion Jimenez Diaz CEIC, Avda. Reyes Catolicos,
2, Entrplanta, 28040 Madrid
Spain 1517 Hospital Universitario Principe de Asturias CEIC,
Ctra. Alcala-Meco s/n, 28805 Alcala de Henares,
Madrid
Spain 1518 CEIC de Aragon, Avda. Gomez Laguna, 25 planta
11, 50009 Zaragoza
Spain 1519 Hospital Universitario de Puerto Real, Ctra. NaI IV,
km. 665, 11510 Puerto Real, Cadiz
Spain 1520 CEIC Hospital Universitario de Getafe (LEC) Ctra.
De Toledo, km. 12500, 28905 Getafe, Madrid
Spain 1521 CEIC Hospital Universitario La Princesa, Findacion
para la Investigacion Biomedica, C/ Diego de leon,
62, 28006 Madrid
Spain 1522 CEIC Hospital Universitario de Girona Josep Trueta
(LEC) avda. De Franca s/n, 17007 Girona
Spain 1523 CEIC Parc Salut del Mar (LEC)
IMIM-Hospital del Mar, Parc de Recerca Biomedica
de Barcelona, Doctor Aiguader, 88, 08003 Barcelona












Switzerland 1701 Kantonal Ethikkommission Aargau Departement
Gesundheit und Soziales PD Dr. med. Otto Hilfiker
Bachstrasse 15
5001 Aarau
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Switzerlan
d
1702 Kantonal Ethik-Kommission (KEK) Prof. Dr. med.




1703 Kantonal Ethik-Kommission (KEK) Prof. Dr. med.
Robert Maurer Universitätsspital Zürich
Sonneggstr. 12 8091 Zürich
Switzerlan
d
1704 Kantonal Ethikkommission Bern (KEK) Prof. Dr.
pharm. Nilaus Tüller Postfach 56 3 Bern
Turkey 1801 Ankara University Medical Faculty Deanship
Clinical Researches Ethics Committee nkara
Universitesi Tip Fakultesi Morfoloji Binası 06100
Sihhiye Ankara Turkey
Turkey 1802 Ege University Medical Faculty Clinical Researches
Ethics Committee Ege Universitesi Tip Fakultesi;
35100 Bornova Izmir
Turkey 1803 Ege University Medical Faculty Clinical Researches
Ethics Committee Ege Universitesi Tip Fakultesi;
35100 Bornova Izmir
Turkey 1804 Ege University Medical Faculty Clinical Researches
Ethics Committee Ege Universitesi Tip Fakultesi;
35100 Bornova Izmir
Turkey 1804 Ege University Medical Faculty Clinical Researches
Ethics Committee Ege Universitesi Tip Fakultesi;
35100 Bornova Izmir
Turkey 1807 Ege University Medical Faculty Clinical Researches
Ethics Committee Ege Universitesi Tip Fakultesi;
35100 Bornova Izmir
Turkey 1810 Ege University Medical Faculty Clinical Researches
Ethics Committee Ege Universitesi Tip Fakultesi;
35100 Bornova Izmir
Turkey 1811 Ege University Medical Faculty Clinical Researches




1901 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1902 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1903 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1904 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1905 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1906 Health Research Authority





1907 Health Research Authority
NRES Committee Riverside REC
Bristol REC Centre




1908 Health Research Authority





1909 Health Research Authority





1910 Health Research Authority





1911 Health Research Authority





1912 Health Research Authority





1913 Health Research Authority





1914 Health Research Authority





1915 Health Research Authority





1916 Health Research Authority





1917 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1918 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1919 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1920 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1921 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1922 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre
Level 3, Block B Whitefriars Lewins Mead Bristol,
BS 1 2NT
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Additional files
Additional file 1: Table S1. Baseline characteristics (ITT population).
(DOCX 12 kb)
Additional file 2: Table S2. Mean (SD) change in estimated GFR (eGFR)
from baseline to month 12 for subpopulations of patients with eGFR
values both time points. (DOCX 12 kb)
Additional file 3: Figure S1. Scatter plot of change in eGFR from
baseline to month 12 according to total IV iron dose in patients
randomized to either high ferritin or low ferritin FCM for patients
with eGFR values at baseline and month 12. The solid line indicates
the linear regression for all points. The dotted line indicates 0 i.e. no
change. eGFR, estimated glomerular filtration rate; FCM, ferric
carboxymaltose. (EPS 1219 kb)
Additional file 4: Figure S2. (a) Ferritin and (b) transferrin saturation
(TSAT) for patients with eGFR values at baseline and month 12 who did
or did not receive alternative anemia therapy or permanently
discontinued study therapy before month 12. BL, baseline; FCM, ferric
carboxymaltose. (ZIP 456 kb)
Additional file 5: Table S3. Selected renal adverse events and serious
adverse events (safety population). (DOCX 11 kb)
Abbreviations
ACE: Angiotensin converting enzyme; ANCOVA: Analysis of covariance;
ARB: Angiotensin II receptor blocker; BMI: Body mass index; CKD: Chronic
kidney disease; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration;
eGFR: estimated GFR; ESA: Erythropoiesis-stimulating agent; FCM: Ferric
carboxymaltose; ITT: Intention-to-treat; IV: Intravenous; MDA: Malondialdehyde;
MDRD: Modification of Diet in Renal Disease; ND-CKD: Non-dialysis
dependent CKD; NTBI: Non-transferrin bound iron; TSAT: Transferrin
saturation
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United
Kingdom
1923 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1924 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1925 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1926 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1927 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1928 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1929 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




19230 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1931 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre




1932 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre
Level 3, Block B Whitefriars Lewins Mead
Bristol, BS 1 2NT
United
Kingdom
1933 Health Research Authority NRES Committee
Riverside REC Bristol REC Centre
Level 3, Block B Whitefriars Lewins Mead
Bristol, BS 1 2NT
Romania 2001 National Ethics Committee for Clinical Study of
Medicine (Comisia Nationala de Etica pentru
Studiul Clinic al Medicamentului) Av. Sanatescu
St., No. 48, 1st district, 011478, Bucharest, Romania
Romania 2002 National Ethics Committee for Clinical Study of
Medicine (Comisia Nationala de Etica pentru
Studiul Clinic al Medicamentului) Av. Sanatescu
St., No. 48, 1st district, 011478, Bucharest, Romania
Romania 2003 National Ethics Committee for Clinical Study of
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Studiul Clinic al Medicamentului) Av. Sanatescu
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Romania 2005 National Ethics Committee for Clinical Study of
Medicine (Comisia Nationala de Etica pentru
Studiul Clinic al Medicamentului) Av. Sanatescu
St., No. 48, 1st district, 011478, Bucharest, Romania
Romania 2006 National Ethics Committee for Clinical Study of
Medicine (Comisia Nationala de Etica pentru
Studiul Clinic al Medicamentului) Av. Sanatescu
St., No. 48, 1st district, 011478, Bucharest, Romania
Romania 2007 National Ethics Committee for Clinical Study of
Medicine (Comisia Nationala de Etica pentru
Studiul Clinic al Medicamentului) Av. Sanatescu
St., No. 48, 1st district, 011478, Bucharest, Romania
US 2110 Salem VA Medical Center IRB Kim Ragsdale, PhD
1970 Roanoke Blvd
Salem. VA 24153
US 2113 Integreview IRB Valerie Nelson
3001, South Lamar Blvd Suite 210 Austin,
TX 78704
US 2105 Integreview IRB Valerie Nelson
3001, South Lamar Blvd Suite 210 Austin,
TX 78704
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Members of the Ferinject® assessment in patients with Iron deficiency
anemia and Non-Dialysis dependent Chronic Kidney Disease (FIND-CKD)
study group are listed in Appendix 1.
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